Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Info
    • Snapshot
    • Quote (Nasdaq)
    • Charts (Nasdaq)
    • Historical Data (Nasdaq)
    • Quote (TSX)
    • Charts (TSX)
    • Historical Data (TSX)
    • Analyst Coverage
  • Filings & Financials
    • Reports
    • SEC Filings
    • SEDAR Filings
    • Tax Information (PFIC)
  • Corporate Governance
  • FAQs
  • Email Alerts
  • IR Contacts
Apr 17, 2020

Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

Apr 2, 2020

Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

Mar 24, 2020

Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

Mar 5, 2020

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Feb 28, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

Jan 27, 2020

Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

Jan 22, 2020

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

Jan 13, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

Jan 9, 2020

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

Dec 12, 2019

Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

RSS
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...59
    © 2023 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap